Impact of lockdown on Covid-19 case fatality rate and viral mutations spread in 7 countries in Europe and North America.


Journal

Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741

Informations de publication

Date de publication:
02 09 2020
Historique:
received: 28 05 2020
accepted: 25 08 2020
entrez: 4 9 2020
pubmed: 4 9 2020
medline: 17 9 2020
Statut: epublish

Résumé

Severe acute respiratory syndrome CoV-2 (SARS-CoV-2) caused the first coronavirus disease 2019 (COVID-19) outbreak in China and has become a public health emergency of international concern. SARS-CoV-2 outbreak has been declared a pandemic by WHO on March 11th, 2020 and the same month several Countries put in place different lockdown restrictions and testing strategies in order to contain the spread of the virus. The calculation of the Case Fatality Rate of SARS-CoV-2 in the Countries selected was made by using the data available at https://github.com/owid/covi-19-data/tree/master/public/data . Case fatality rate was calculated as the ratio between the death cases due to COVID-19, over the total number of SARS-CoV-2 reported cases 14 days before. Standard Case Fatality Rate values were normalized by the Country-specific ρ factor, i.e. the number of PCR tests/1 million inhabitants over the number of reported cases/1 million inhabitants. Case-fatality rates between Countries were compared using proportion test. Post-hoc analysis in the case of more than two groups was performed using pairwise comparison of proportions and p value was adjusted using Holm method. We also analyzed 487 genomic sequences from the GISAID database derived from patients infected by SARS-CoV-2 from January 2020 to April 2020 in Italy, Spain, Germany, France, Sweden, UK and USA. SARS-CoV-2 reference genome was obtained from the GenBank database (NC_045512.2). Genomes alignment was performed using Muscle and Jalview software. We, then, calculated the Case Fatality Rate of SARS-CoV-2 in the Countries selected. In this study we analyse how different lockdown strategies and PCR testing capability adopted by Italy, France, Germany, Spain, Sweden, UK and USA have influenced the Case Fatality Rate and the viral mutations spread. We calculated case fatality rates by dividing the death number of a specific day by the number of patients with confirmed COVID-19 infection observed 14 days before and normalized by a ρ factor which takes into account the diagnostic PCR testing capability of each Country and the number of positive cases detected. We notice the stabilization of a clear pattern of mutations at sites nt241, nt3037, nt14408 and nt23403. A novel nonsynonymous SARS-CoV-2 mutation in the spike protein (nt24368) has been found in genomes sequenced in Sweden, which enacted a soft lockdown strategy. Strict lockdown strategies together with a wide diagnostic PCR testing of the population were correlated with a relevant decline of the case fatality rate in different Countries. The emergence of specific patterns of mutations concomitant with the decline in case fatality rate needs further confirmation and their biological significance remains unclear.

Sections du résumé

BACKGROUND
Severe acute respiratory syndrome CoV-2 (SARS-CoV-2) caused the first coronavirus disease 2019 (COVID-19) outbreak in China and has become a public health emergency of international concern. SARS-CoV-2 outbreak has been declared a pandemic by WHO on March 11th, 2020 and the same month several Countries put in place different lockdown restrictions and testing strategies in order to contain the spread of the virus.
METHODS
The calculation of the Case Fatality Rate of SARS-CoV-2 in the Countries selected was made by using the data available at https://github.com/owid/covi-19-data/tree/master/public/data . Case fatality rate was calculated as the ratio between the death cases due to COVID-19, over the total number of SARS-CoV-2 reported cases 14 days before. Standard Case Fatality Rate values were normalized by the Country-specific ρ factor, i.e. the number of PCR tests/1 million inhabitants over the number of reported cases/1 million inhabitants. Case-fatality rates between Countries were compared using proportion test. Post-hoc analysis in the case of more than two groups was performed using pairwise comparison of proportions and p value was adjusted using Holm method. We also analyzed 487 genomic sequences from the GISAID database derived from patients infected by SARS-CoV-2 from January 2020 to April 2020 in Italy, Spain, Germany, France, Sweden, UK and USA. SARS-CoV-2 reference genome was obtained from the GenBank database (NC_045512.2). Genomes alignment was performed using Muscle and Jalview software. We, then, calculated the Case Fatality Rate of SARS-CoV-2 in the Countries selected.
RESULTS
In this study we analyse how different lockdown strategies and PCR testing capability adopted by Italy, France, Germany, Spain, Sweden, UK and USA have influenced the Case Fatality Rate and the viral mutations spread. We calculated case fatality rates by dividing the death number of a specific day by the number of patients with confirmed COVID-19 infection observed 14 days before and normalized by a ρ factor which takes into account the diagnostic PCR testing capability of each Country and the number of positive cases detected. We notice the stabilization of a clear pattern of mutations at sites nt241, nt3037, nt14408 and nt23403. A novel nonsynonymous SARS-CoV-2 mutation in the spike protein (nt24368) has been found in genomes sequenced in Sweden, which enacted a soft lockdown strategy.
CONCLUSIONS
Strict lockdown strategies together with a wide diagnostic PCR testing of the population were correlated with a relevant decline of the case fatality rate in different Countries. The emergence of specific patterns of mutations concomitant with the decline in case fatality rate needs further confirmation and their biological significance remains unclear.

Identifiants

pubmed: 32878627
doi: 10.1186/s12967-020-02501-x
pii: 10.1186/s12967-020-02501-x
pmc: PMC7463225
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

338

Commentaires et corrections

Type : CommentIn

Références

Cell Res. 2020 Apr;30(4):343-355
pubmed: 32231345
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
J Virol. 2006 Apr;80(7):3225-37
pubmed: 16537590
Swiss Med Wkly. 2020 Feb 07;150:w20203
pubmed: 32031234
Lancet Infect Dis. 2020 Jul;20(7):773
pubmed: 32171390
N Engl J Med. 2003 May 15;348(20):1967-76
pubmed: 12690091
Trends Microbiol. 2016 Jun;24(6):490-502
pubmed: 27012512
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Lancet. 2003 Jul 26;362(9380):263-70
pubmed: 12892955
N Engl J Med. 2003 May 15;348(20):1953-66
pubmed: 12690092
J Virol. 2013 Jul;87(14):7790-2
pubmed: 23678167
Proc Natl Acad Sci U S A. 2004 Jun 1;101(22):8455-60
pubmed: 15150417
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
J Transl Med. 2020 Apr 22;18(1):179
pubmed: 32321524

Auteurs

Maria Pachetti (M)

Elettra Sincrotrone Trieste-Area Science Park, Trieste, Italy.
Department of Physics, University of Trieste, Via Valerio 2, Trieste, Italy.

Bruna Marini (B)

Ulisse BioMed-Area Science Park, Trieste, Italy.

Fabiola Giudici (F)

Department of Medicine, Surgery and Health Science, University of Trieste, Trieste, Italy.

Francesca Benedetti (F)

Institute of Human Virology, Department of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, USA.

Silvia Angeletti (S)

Medical Statistic and Molecular Epidemiology Unit, University of Biomedical Campus, Rome, Italy.

Massimo Ciccozzi (M)

Medical Statistic and Molecular Epidemiology Unit, University of Biomedical Campus, Rome, Italy.

Claudio Masciovecchio (C)

Elettra Sincrotrone Trieste-Area Science Park, Trieste, Italy.

Rudy Ippodrino (R)

Department of Medicine, Surgery and Health Science, University of Trieste, Trieste, Italy. r.ippodrino@ulissebiomed.com.

Davide Zella (D)

Institute of Human Virology, Department of Biochemistry and Molecular Biology, School of Medicine, University of Maryland, Baltimore, USA. dzella@ihv.umaryland.edu.
Member of the Global Virus Network, Baltimore, USA. dzella@ihv.umaryland.edu.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH